Article ; Online: Elexacaftor/Tezacaftor/Ivacaftor use in Pediatric Cystic Fibrosis Patients with Advanced Liver Disease.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2024
Abstract: ... change in ppFEV1 from prior to ETI to highest value during therapy was 14.27 % (4.25) (p = 0.007 ... When evaluating the group as whole, AST decreased from baseline to last reported -15.18 (23.23) units/L (p = 0.054 ... and ALT slightly increased 0.73 (39.13) units/L (p = 0.96). Bilirubin increased minimally overall ...
Abstract | Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy extends the life expectancy of people with cystic fibrosis (PwCF). However, CFTR modulators have not been well studied in patients with cystic fibrosis liver disease (CFLD), specifically those with advanced liver disease with portal hypertension. The purpose of this report is to describe the use of elexacaftor/tezacaftor/ivacaftor (ETI) in pediatric CF patients with advanced CFLD. Methods: This retrospective case series included PwCF < 18 years old with baseline advanced CFLD initiated on ETI. Results: Eleven PwCF and advanced CFLD were treated with ETI; six started a reduced dose regimen. No patient required treatment interruption and four patients received dose changes related to increase in transaminase and/or bilirubin elevations. Mean (SD) change in ppFEV1 from prior to ETI to highest value during therapy was 14.27 % (4.25) (p = 0.007). When evaluating the group as whole, AST decreased from baseline to last reported -15.18 (23.23) units/L (p = 0.054) and ALT slightly increased 0.73 (39.13) units/L (p = 0.96). Bilirubin increased minimally overall for patients with mean change from baseline of 0.83 (1.33) mg/dL [range -0.5-3] (p = 0.17). A model for time on ETI showed a significant decrease in AST over time of 0.955 per month of ETI but no other liver biochemistries were significant. No patient experienced decompensation of CFLD. Conclusion: ETI therapy in pediatric CF patients with advanced CFLD can be beneficial in improving pulmonary and nutritional outcomes without negative impact on liver biochemistries or hepatic outcomes. Close monitoring is recommended to ensure safety and tolerability. |
---|---|
Language | English |
Publishing date | 2024-04-04 |
Publishing country | Netherlands |
Document type | Journal Article |
ZDB-ID | 2084724-5 |
ISSN | 1873-5010 ; 1569-1993 |
ISSN (online) | 1873-5010 |
ISSN | 1569-1993 |
DOI | 10.1016/j.jcf.2024.03.011 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6028: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 459: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.